KYNTRA BIO INC
KYNBNASDAQπ #4909 by market capUS Equity
$1.71β
Last available close Β· quote unavailableTrack KYNB
Get earnings, price moves & breaking news on Telegram
24hβ
7dβΌ 52.5%
14dβΌ 54.9%
30dβΌ 64.7%
ytdβΌ 80.5%
1yβΌ 79.9%
π¦Market Cap
$6M
Small Cap
πRevenue Growth (YoY)
-78.3%
Declining
πGross Margin
19.6%
Thin
π΅FCF Margin
-913.6%
Thin
βοΈP/S Ratio
1.2x
Cheap
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- β
- 52-Week Range
- $1.54 β $10.47
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 4.0M
- Next Earnings
- β
Fundamentals Snapshot
- Annual Revenue
- $6M
- Last Q Revenue
- β
- P/E Ratio
- 0.2
- P/S Ratio
- 1.2x
- EPS (TTM)
- $8.61
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +0.2%
KYNTRA BIO INC
KYNBFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$6MβΌ β78.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
91.4%β² +92.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$46MβΌ β69.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$5MβΌ β96.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
4.0Mβ² +0.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$48Mβ² +$70M YoY
About KYNTRA BIO INC
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst data unavailable.
Latest News & Updates
News unavailable.